Success Metrics

Clinical Success Rate
92.9%

Based on 13 completed trials

Completion Rate
93%(13/14)
Active Trials
0(0%)
Results Posted
38%(5 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_4
11
61%
Ph phase_1
1
6%
Ph phase_3
4
22%

Phase Distribution

1

Early Stage

0

Mid Stage

15

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
1(6.3%)
Phase 3Large-scale testing
4(25.0%)
Phase 4Post-market surveillance
11(68.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.9%

13 of 14 finished

Non-Completion Rate

7.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Completed(13)
Terminated(1)
Other(4)

Detailed Status

Completed13
unknown4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
92.9%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (6.3%)
Phase 34 (25.0%)
Phase 411 (68.8%)

Trials by Status

terminated16%
completed1372%
unknown422%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT02967224Phase 4

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin

Completed
NCT02967211Phase 4

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin

Completed
NCT02910518Phase 1

A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus

Completed
NCT03350984Phase 4

Insulin Schemes for Type 2 Diabetes Control

Completed
NCT04664764Phase 4

Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.

Unknown
NCT03511521Phase 4

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

Terminated
NCT02451917Phase 4

Glargine Versus NPH in Patients With Chronic Kidney Disease

Completed
NCT03220425Phase 3

Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

Completed
NCT00474045Phase 3

Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes

Completed
NCT01810952Phase 4

The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients

Completed
NCT00115570Phase 3

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

Completed
NCT02607410Phase 4

Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D

Completed
NCT01223131Phase 3

Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.

Completed
NCT01500850Phase 4

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

Unknown
NCT00935805

Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy

Unknown
NCT01271517Phase 4

Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis

Unknown
NCT00941148Phase 4

Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin

Completed
NCT00468364

Comparison of Insulin Glargine and NPH Insulin at Night and at Hypoglycemia in Type 2 Diabetes

Completed

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18